Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.

Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT.

Nitric Oxide. 2018 May 31;78:72-80. doi: 10.1016/j.niox.2018.05.009. [Epub ahead of print] Review.

2.

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.

Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.

J Pharmacol Exp Ther. 2018 Jun;365(3):664-675. doi: 10.1124/jpet.117.247429. Epub 2018 Apr 11.

PMID:
29643251
3.

The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.

Flores-Costa R, Alcaraz-Quiles J, Titos E, López-Vicario C, Casulleras M, Duran-Güell M, Rius B, Diaz A, Hall K, Shea C, Sarno R, Currie M, Masferrer JL, Clària J.

Br J Pharmacol. 2018 Mar;175(6):953-967. doi: 10.1111/bph.14137. Epub 2018 Jan 31.

4.

Renal effects induced by prolonged mPGES1 inhibition.

Salazar F, Vazquez ML, Masferrer JL, Mbalaviele G, Llinas MT, Saez F, Arhancet G, Salazar FJ.

Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F68-74. doi: 10.1152/ajprenal.00492.2013. Epub 2013 Nov 6.

5.

pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood.

Zhu M, Pleasic-Williams S, Lin TH, Wunderlich DA, Cheng JB, Masferrer JL.

J Transl Med. 2013 Mar 14;11:65. doi: 10.1186/1479-5876-11-65.

6.

Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low.

Salazar F, Salazar FJ, Saez F, Reverte V, Zweifel B, Dufield D, Radabaugh M, Graneto M, Llinas MT, Masferrer JL.

J Cardiovasc Pharmacol. 2013 Apr;61(4):329-36. doi: 10.1097/FJC.0b013e31828399ae.

PMID:
23288201
7.

Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis.

Staten NR, Welsh EA, Sidik K, McDonald SA, Dufield DR, Maqsodi B, Ma Y, McMaster GK, Mathews RW, Arch RH, Masferrer JL, Souberbielle BE.

Fibrogenesis Tissue Repair. 2012 Dec 27;5(1):21. doi: 10.1186/1755-1536-5-21.

8.

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.

Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):1114-9. doi: 10.1016/j.bmcl.2012.11.109. Epub 2012 Dec 6.

PMID:
23260349
9.

Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.

Radi ZA, Heuvelman DM, Masferrer JL, Benson EL.

Dig Dis Sci. 2011 Aug;56(8):2283-91. doi: 10.1007/s10620-011-1628-8. Epub 2011 Mar 5.

PMID:
21374065
10.

High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry.

Highkin MK, Yates MP, Nemirovskiy OV, Lamarr WA, Munie GE, Rains JW, Masferrer JL, Nagiec MM.

J Biomol Screen. 2011 Feb;16(2):272-7. doi: 10.1177/1087057110391656.

PMID:
21297110
11.

Anti-PDGF-B monoclonal antibody reduces liver fibrosis development.

Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, Moffat MA, Katragadda M, Violand BN, Arch RH, Masferrer JL.

Hepatol Res. 2010 Nov;40(11):1128-41. doi: 10.1111/j.1872-034X.2010.00718.x. Epub 2010 Sep 28.

PMID:
20880061
12.

Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.

Wang X, Heuvelman DM, Carroll JA, Dufield DR, Masferrer JL.

Cancer Invest. 2010 Jul;28(6):635-41. doi: 10.3109/07357901003630983.

PMID:
20394503
13.

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.

Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M.

J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. doi: 10.1124/jpet.110.166967. Epub 2010 Apr 8.

PMID:
20378715
14.

Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.

Rajagopalan LE, Davies MS, Kahn LE, Kornmeier CM, Shimada H, Steiner TA, Zweifel BS, Wendling JM, Payne MA, Loeffler RF, Case BL, Norton MB, Parikh MD, Nemirovskiy OV, Mourey RJ, Masferrer JL, Misko TP, Kolodziej SA.

J Pharmacol Exp Ther. 2010 Jun;333(3):707-16. doi: 10.1124/jpet.110.166033. Epub 2010 Mar 12.

PMID:
20228155
15.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL.

Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

PMID:
20067770
16.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):59-67. doi: 10.1016/j.ejphar.2009.06.058. Epub 2009 Jul 4.

PMID:
19580807
17.

Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.

Anderson GD, Keys KL, De Ciechi PA, Masferrer JL.

Inflamm Res. 2009 Feb;58(2):109-17. doi: 10.1007/s00011-009-8149-3.

PMID:
19184362
18.

A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.

Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL.

Eur J Pharmacol. 2008 Apr 14;584(1):166-74. doi: 10.1016/j.ejphar.2008.01.021. Epub 2008 Feb 5.

PMID:
18295198
19.

Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.

Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J.

J Pharmacol Exp Ther. 2007 Dec;323(3):778-86. Epub 2007 Aug 31.

PMID:
17766677
20.

Development of a fluorescence-based enzyme assay of human 5-lipoxygenase.

Pufahl RA, Kasten TP, Hills R, Gierse JK, Reitz BA, Weinberg RA, Masferrer JL.

Anal Biochem. 2007 May 15;364(2):204-12. Epub 2007 Feb 14.

PMID:
17376394
21.

The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, Rodés J.

FASEB J. 2005 Jul;19(9):1120-2. Epub 2005 May 4.

PMID:
15876570
22.

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.

López-Parra M, Clària J, Titos E, Planagumà A, Párrizas M, Masferrer JL, Jiménez W, Arroyo V, Rivera F, Rodés J.

J Hepatol. 2005 Jan;42(1):75-81.

PMID:
15629510
23.

Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling.

Paccani SR, Patrussi L, Ulivieri C, Masferrer JL, D'Elios MM, Baldari CT.

Blood. 2005 Mar 1;105(5):2042-8. Epub 2004 Oct 28.

24.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
25.

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL.

Cancer Res. 2004 Jan 1;64(1):279-85.

26.

Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.

Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL.

J Pharmacol Exp Ther. 2004 Mar;308(3):929-34. Epub 2004 Jan 7.

PMID:
14711936
27.

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91.

28.

Cyclooxygenase-2 inhibitors in cancer prevention and treatment.

Masferrer JL.

Adv Exp Med Biol. 2003;532:209-13. Review. No abstract available.

PMID:
12908559
29.

COX-2 inhibitors as radiosensitizing agents for cancer therapy.

Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL.

Am J Clin Oncol. 2003 Aug;26(4):S58-61. Review.

PMID:
12902857
30.
31.

Renal effects of selective cyclooxygenase inhibition in experimental liver disease.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Arroyo V, Rivera F, Rodés J.

Adv Exp Med Biol. 2003;525:133-6. No abstract available.

PMID:
12751752
32.

Cyclooxygenase-2 in human pathological disease.

Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL.

Adv Exp Med Biol. 2002;507:177-84. Review.

PMID:
12664583
33.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

34.

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL.

Cancer Res. 2002 Oct 15;62(20):5778-84.

35.

Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.

Cancer Res. 2002 Oct 1;62(19):5405-7.

36.

Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.

Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL.

Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. Review.

PMID:
12051953
37.

Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Koki AT, Masferrer JL.

Cancer Control. 2002 Mar-Apr;9(2 Suppl):28-35. Review.

PMID:
11965228
38.

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Altuna R, Arroyo V, Rivera F, Rodés J.

Br J Pharmacol. 2002 Feb;135(4):891-900.

39.

Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.

Anticancer Res. 2001 Sep-Oct;21(5):3425-32.

PMID:
11848504
40.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

41.

Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.

Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT.

Scand J Gastroenterol. 2001 Aug;36(8):865-9.

PMID:
11495083
42.

Cyclooxygenase-2 is overexpressed in human cervical cancer.

Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ.

Clin Cancer Res. 2001 Feb;7(2):429-34.

43.

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.

Koki AT, Leahy KM, Masferrer JL.

Expert Opin Investig Drugs. 1999 Oct;8(10):1623-1638.

PMID:
11139815
44.

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K.

Cancer Res. 2000 Oct 15;60(20):5599-602.

45.

Anti-inflammatories for cardiovascular disease.

Masferrer JL, Needleman P.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12400-1. Review. No abstract available.

46.

Role of cyclooxygenases in angiogenesis.

Leahy KM, Koki AT, Masferrer JL.

Curr Med Chem. 2000 Nov;7(11):1163-70. Review.

PMID:
11032965
47.

Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.

Khanna IK, Yu Y, Huff RM, Weier RM, Xu X, Koszyk FJ, Collins PW, Cogburn JN, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K, Veenhuizen AW, Yuan J, Yang DC, Zhang YY.

J Med Chem. 2000 Aug 10;43(16):3168-85.

PMID:
10956225
48.

Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.

Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L.

Cancer Res. 2000 Mar 1;60(5):1326-31.

49.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K.

Cancer Res. 2000 Mar 1;60(5):1306-11.

50.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.

J Med Chem. 2000 Mar 9;43(5):775-7. No abstract available.

PMID:
10715145

Supplemental Content

Loading ...
Support Center